SCHEMBL22453383

SCHEMBL22453383

Cc1ccc(Nc2c(C(=O)N3CC(O)C3)ccc(F)c2F)c(F)c1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 19/20 0.76
MAP2K2 P36507 17/20 0.76
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
BRAF P15056 1/20 0.46
DRD1 P21728 1/20 0.46
TBXA2R P21731 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRM1 P35372 1/20 0.46
DRD3 P35462 1/20 0.46
ACTR3 P61158 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KCNH2 Q12809 1/20 0.46
CPS1 P31327 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23707602 0.90 MAP2K1 (0.66) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL18968395 0.90 MAP2K1 (0.62) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL29413551 0.86 MAP2K1 (1.00) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL189188 0.86 MAP2K1 (1.00) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL18968387 0.86 MAP2K1 (0.58) MAP2K1MAP2K2CHRM2CHRM1BRAF
Hydrochloric Acid SCHEMBL29413470 0.85 MAP2K1 (0.98) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL18968425 0.85 MAP2K1 (0.57) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL18968032 0.85 MAP2K2 (0.57) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL23398087 0.85 MAP2K2 (0.70) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL18968353 0.84 MAP2K1 (0.56) MAP2K1MAP2K2CHRM2CHRM1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023159184-A1 DRUG COMBINATIONS AND METHODS OF TREATING OVARIAN CANCER Pattern Computer, Inc. (US) 2023-08-24 WO disclosed
WO-2023078881-A1 NOVEL USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2023-05-11 WO disclosed
WO-2020187674-A1 CRYSTALLINE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDIN-2-YL)AZETIDIN-1-YL]METHANONE HEMISUCCINATE SANDOZ AG (CH) 2020-09-24 WO disclosed